Cite
HARVARD Citation
Yashar, D. et al. (2022). A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Leukemia & lymphoma. 63 (4), pp. 975-983. [Online].